The collaboration leverages Neuberg’s extensive laboratory network to deploy the elive platform, a technology designed to predict how patient tumors respond to immunotherapy. Under the agreement, Neuberg will process tumor biopsy samples at its flagship Ahmedabad facility, generating localized data to support broader clinical adoption. This integration allows oncologists to move beyond standard molecular profiling by observing live tissue reactions to various treatments.
Elephas Biosciences Partners with Neuberg Diagnostics for India Expansion
Madison-based Elephas Biosciences has secured an exclusive partnership with India’s Neuberg Diagnostics to integrate its live tissue platform into the Indian oncology market. By combining functional tumor testing with molecular profiling, the companies aim to launch clinical immunotherapy response assessments in India by late 2026.
For Maneesh Arora, founder and CEO of Elephas, the move represents a critical expansion of the company’s global footprint. Dr. Sandip Shah, Joint Managing Director of Neuberg Diagnostics, noted that the platform addresses a persistent challenge in cancer care: identifying which patients will benefit from specific immunotherapies. By processing over 30 million tests annually across its 250-lab network, Neuberg provides the infrastructure necessary to bring this functional precision medicine to a wider patient population.
Comments (0)
No comments yet. Be the first!